<DOC>
	<DOCNO>NCT01341652</DOCNO>
	<brief_summary>The investigator try find new method treat prostate cancer . The approach investigator take try enhance patient ' immune response cancer . In study investigator test effectiveness vaccine may able help body fight prostate cancer .</brief_summary>
	<brief_title>Phase II PAP Plus GM-CSF Versus GM-CSF Alone Non-metastatic Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Histologic diagnosis adenocarcinoma prostate Completion local therapy surgery and/or ablative radiation therapy least 3 month prior entry , removal ablation visible disease , include seminal vesical and/or local lymph node involvement Rising prostate specific antigen ( PSA ) level without scan evidence metastatic disease Asymptomatic mildly symptomatic life expectancy least 4 month Small cell variant prostate cancer histology Evidence immunosuppression Prior treatment androgen deprivation except give neoadjuvantly adjuvantly radiation therapy time prostatectomy . In situation , 24 month androgen deprivation must give treatment must within 12 month prior screen study . Serum testosterone screen &lt; 50 ng/dL Known bone metastases lymph node involvement determine bone scan compute tomography ( CT ) scan abdomen pelvis within 4 week study entry Prior vaccine therapy prostate cancer Known allergic reaction granulocytemacrophage colonystimulating factor ( GMCSF ) Severe intercurrent medical condition laboratory abnormality would impart , judgment Medical Monitor , excess risk associate study participation study agent administration</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>